K. Patil

PD36-06 IS FOUR DAYS HOSPITAL STAY AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY FEASIBLE? A MULTIDISCIPLINARY ENHANCED RECOVERY PROGRAM CHALLENGE

Overall survival was estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS: A total of 56 patients were identified for this study. 14 of the 56 patients (25%) who underwent adjuvant cisplatin-based chemotherapy were determined to be sarcopenic. Overall survival after the start of adjuvant therapy for sarcopenic patients was 25.12 months, as compared to non-sarcopenic patients who demonstrated an overall survival of 44.30 months (p<0.05). The 5-year survival rates were 21% and 36% for the two groups, respectively. While the time to local and distant recurrences was greater in the non-sarcopenic patients, as compared to those with sarcopenia, there was no statistically significant difference. CONCLUSIONS: Our analysis has indicated that patients with sarcopenia have a worse overall survival when treated with adjuvant chemotherapy after radical cystectomy. In order to conclude whether sarcopenic patients should be receiving adjuvant therapy, future studies must match these patients with sarcopenic patients who met criteria to receive adjuvant chemotherapy after radical cystectomy, yet decided to forego treatment.